Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Alexandra Oltová"'
Autor:
Miroslav Boudny, Jana Zemanova, Prashant Khirsariya, Marek Borsky, Jan Verner, Jana Cerna, Alexandra Oltova, Vaclav Seda, Marek Mraz, Josef Jaros, Zuzana Jaskova, Michaela Spunarova, Yvona Brychtova, Karel Soucek, Stanislav Drapela, Marie Kasparkova, Jiri Mayer, Kamil Paruch, Martin Trbusek
Publikováno v:
Haematologica, Vol 104, Iss 12 (2019)
Introduction of small-molecule inhibitors of B-cell receptor signaling and BCL2 protein significantly improves therapeutic options in chronic lymphocytic leukemia. However, some patients suffer from adverse effects mandating treatment discontinuation
Externí odkaz:
https://doaj.org/article/e872ad7d936f40299c20d4bb02b9ef06
Autor:
Ester Mejstrikova, Jana Volejnikova, Eva Fronkova, Katerina Zdrahalova, Tomas Kalina, Jaroslav Sterba, Yahia Jabali, Vladimir Mihal, Bohumir Blazek, Zdena Cerna, Daniela Prochazkova, Jiri Hak, Zuzana Zemanova, Marie Jarosova, Alexandra Oltova, Petr Sedlacek, Jiri Schwarz, Jan Zuna, Jan Trka, Jan Stary, Ondrej Hrusak
Publikováno v:
Haematologica, Vol 95, Iss 6 (2010)
Background Mixed phenotype acute leukemia (MPAL) represents a diagnostic and therapeutic dilemma. The European Group for the Immunological Classification of Leukemias (EGIL) scoring system unambiguously defines MPAL expressing aberrant lineage marker
Externí odkaz:
https://doaj.org/article/00e3c2b1f9cb4fb2adcf9b49b33ebc86
Autor:
Stanislav Drápela, Miroslav Boudny, Josef Jaroš, Michaela Špunarová, Jan Verner, Prashant Khirsariya, Zuzana Jašková, Kamil Paruch, Yvona Brychtová, Marie Kasparkova, Jana Zemanová, Jiri Mayer, Marek Borsky, Václav Šeda, Jana Černá, Martin Trbušek, Alexandra Oltová, Marek Mráz, Karel Souček
Publikováno v:
Haematologica
Introduction of small-molecule inhibitors of B-cell receptor signaling and BCL2 protein significantly improves therapeutic options in chronic lymphocytic leukemia. However, some patients suffer from adverse effects mandating treatment discontinuation
Autor:
Yvona Brychtová, Alexandra Oltová, Pavel Vesely, Jan Verner, Martin Trbušek, Kristina Zaprazna, Pavlína Janovská, Jiri Kohoutek, Zuzana Jašková, Marek Borsky, Ondrej Hylse, Vitezslav Bryja, Kamil Paruch, Marta Dzimkova, Marie Kasparkova, Jana Zemanová, Jana Collakova
Publikováno v:
Oncotarget
Oncotarget. 2016, vol. 7, issue 38, p. 1-16.
Oncotarget. 2016, vol. 7, issue 38, p. 1-16.
// Jana Zemanova 1 , Ondrej Hylse 2, 3 , Jana Collakova 4, 5 , Pavel Vesely 5 , Alexandra Oltova 1 , Marek Borsky 1 , Kristina Zaprazna 6 , Marie Kasparkova 1 , Pavlina Janovska 7 , Jan Verner 1 , Jiri Kohoutek 8 , Marta Dzimkova 8 , Vitezslav Bryja
Autor:
Jana Kotašková, Yvona Brychtová, Marek Borsky, Helena Kočková, Boris Tichy, Michael Doubek, Kamila Brázdilová, Alexandra Oltová, Vasilis Bikos, Šárka Pospíšilová, H Skuhrova Francova, Jiří Mayer, Jitka Malčíková, Karla Plevová
Publikováno v:
Leukemia
Multiple productive IGH rearrangements denote oligoclonality even in immunophenotypically monoclonal CLL
Autor:
Kamila Stránská, Martina Buresova, Kamila Réblová, Jitka Malčíková, Michael L. Atchison, Alexandra Oltová, Tomáš Loja, Šárka Pospíšilová, Veronika Svobodová, Nikola Tom, Kristina Durechova, Kristina Zaprazna, Michael Doubek, Lenka Radová, Martin Trbušek, Vojtech Bystry, Jiri Baloun
Publikováno v:
Ann Hematol
Activation-induced cytidine deaminase (AID) is a mutator enzyme essential for somatic hypermutation (SHM) and class switch recombination (CSR) during effective adaptive immune responses. Its aberrant expression and activity have been detected in lymp
Autor:
Yvona Brychtová, Martin Trbušek, Lukas Smolej, Jitka Malčíková, Anna Panovská, Jana Chovancová, Jana Šmardová, Petra Obrtlikova, Ludmila Šebejová, Eva Jelinkova, Michael Doubek, Jakub Trizuljak, Markéta Hadrabová, Pavlína Volfová, Jiri Mayer, Denisa Bakesova, Šárka Pospíšilová, Josef Karban, Alexandra Oltová, Karla Plevová, Marek Mráz, Olga Stehlíková
Publikováno v:
American Journal of Hematology. 90:417-421
The treatment of relapsed/refractory chronic lymphocytic leukemia (CLL) remains a challenging clinical issue. An important treatment option is the use of high-dose corticosteroids. The purpose of this clinical trial was to determine the efficacy and
Autor:
Regina Fillerova, Lenka Kruzova, Tomas Papajik, Michael Doubek, Daniel Lysák, Martina Hruba, Marek Mráz, Vít Procházka, Marie Jarošová, Eva Koritakova, Karel Indrak, Alexandra Oltová, Eva Kriegova, Karla Plevová
Publikováno v:
American Journal of Hematology. 92
Detection of genetic changes has improved the current risk stratification in chronic lymphocytic leukemia (CLL).1,2 Among the known recurrent chromosomal abnormalities,1 6q deletion is less frequent and controversy surrounding its prognostic signific
Autor:
Michael Doubek, Anna Panovská, Šárka Pospíšilová, Alexandra Oltová, Kristina Štěpanovská, Martin Brejcha, Gabriela Vaňková, Yvona Brychtová, Kateřina Horká, Jiří Mayer, Martina Stoklasová, Karla Plevová
Publikováno v:
Leukemia Research; Vol 38
Leukemia Research
Leukemia Research
Chronic lymphocytic leukemia (CLL) patients may acquire new chromosome abnormalities during the course of their disease. Clonal evolution (CE) has been detected by conventional chromosome banding (CBA), several groups also confirmed CE with fluoresce
Autor:
Petra Šmuhařová, Eva Divíšková, Vladimíra Vallová, Lenka Tomášiková, Veronika Némethová, Alexandra Oltová, Michael Doubek, Jiří Mayer, Gabriela Vaňková, Šárka Pospíšilová, Kristina Štěpanovská, Karla Plevová, Petr Kuglík
Publikováno v:
Europe PubMed Central
Background Chromosomal aberrations play an important role as prognostic factors in chronic lymphocytic leukemia (CLL). These aberrations are mostly detected by fluorescent in situ hybridization (FISH), as chromosomal banding analysis has been scarce